19-49635587-C-T
Variant summary
Our verdict is Likely benign. Variant got -2 ACMG points: 2P and 4B. PM2BP4_Strong
The ENST00000246792.4(RRAS):c.646G>A(p.Val216Ile) variant causes a missense change involving the alteration of a non-conserved nucleotide. The variant allele was found at a frequency of 0.0000222 in 1,443,756 control chromosomes in the GnomAD database, including 1 homozygotes. In-silico tool predicts a benign outcome for this variant. 15/21 in silico tools predict a benign outcome for this variant. Variant has been reported in ClinVar as Uncertain significance (★★).
Frequency
Consequence
ENST00000246792.4 missense
Scores
Clinical Significance
Conservation
Genome browser will be placed here
ACMG classification
Verdict is Likely_benign. Variant got -2 ACMG points.
Transcripts
RefSeq
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | MANE | Protein | UniProt |
---|---|---|---|---|---|---|---|---|
RRAS | NM_006270.5 | c.646G>A | p.Val216Ile | missense_variant | 6/6 | ENST00000246792.4 | NP_006261.1 |
Ensembl
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | TSL | MANE | Protein | Appris | UniProt |
---|---|---|---|---|---|---|---|---|---|---|
RRAS | ENST00000246792.4 | c.646G>A | p.Val216Ile | missense_variant | 6/6 | 1 | NM_006270.5 | ENSP00000246792 | P1 |
Frequencies
GnomAD3 genomes AF: 0.0000396 AC: 6AN: 151646Hom.: 1 Cov.: 31
GnomAD3 exomes AF: 0.0000450 AC: 7AN: 155500Hom.: 0 AF XY: 0.0000608 AC XY: 5AN XY: 82174
GnomAD4 exome AF: 0.0000201 AC: 26AN: 1292110Hom.: 0 Cov.: 30 AF XY: 0.0000238 AC XY: 15AN XY: 630012
GnomAD4 genome AF: 0.0000396 AC: 6AN: 151646Hom.: 1 Cov.: 31 AF XY: 0.0000541 AC XY: 4AN XY: 73970
ClinVar
Submissions by phenotype
not specified Uncertain:1
Uncertain significance, criteria provided, single submitter | clinical testing | Ambry Genetics | Dec 15, 2022 | The c.646G>A (p.V216I) alteration is located in exon 6 (coding exon 6) of the RRAS gene. This alteration results from a G to A substitution at nucleotide position 646, causing the valine (V) at amino acid position 216 to be replaced by an isoleucine (I). Based on insufficient or conflicting evidence, the clinical significance of this alteration remains unclear. - |
Noonan syndrome Uncertain:1
Uncertain significance, criteria provided, single submitter | clinical testing | Labcorp Genetics (formerly Invitae), Labcorp | May 30, 2022 | In summary, the available evidence is currently insufficient to determine the role of this variant in disease. Therefore, it has been classified as a Variant of Uncertain Significance. Algorithms developed to predict the effect of missense changes on protein structure and function output the following: SIFT: "Tolerated"; PolyPhen-2: "Benign"; Align-GVGD: "Class C0". The isoleucine amino acid residue is found in multiple mammalian species, which suggests that this missense change does not adversely affect protein function. ClinVar contains an entry for this variant (Variation ID: 1366588). This variant has not been reported in the literature in individuals affected with RRAS-related conditions. This variant is present in population databases (rs748655822, gnomAD 0.01%). This sequence change replaces valine, which is neutral and non-polar, with isoleucine, which is neutral and non-polar, at codon 216 of the RRAS protein (p.Val216Ile). - |
Computational scores
Source:
Splicing
Find out detailed SpliceAI scores and Pangolin per-transcript scores at